SCI Abstract

search
Prophylactic management of patients with von Willebrand disease
Prophylactic management of patients with von Willebrand disease
Von Willebrand disease, the most common inherited bleeding disorder that affects both males and females, is due to quantit...
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mita...
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant p...
Bortezomib in autoimmune hemolytic anemia and beyond
Bortezomib in autoimmune hemolytic anemia and beyond
Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multip...
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
1. Rodriguez-Abreu, D, Bordoni, A, Zucca, E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18(Suppl. 1): i3–...
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) is n...
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed agains...
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand sy...
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of...